XNAS
XCUR
Market cap6mUSD
Oct 08, Last price
1.00USD
1D
-1.96%
1Q
-42.86%
IPO
-99.78%
Name
Exicure Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
16.72%
Rev. gr., 5y
-17.34%
Revenues
0
-100.00%
Net income
-5m
L-49.02%
CFO
-9m
L+193.99%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Key people
Josephine Cardarelli
President, Chief Scientific Officer · since 2025
Seung Ik Baik
Chief Financial Officer, Secretary, Director · since 2024
Chang Keun Choi
Director · since 2024
Ho Jung
Director · since 2024
Minwoo Kang
Director · since 2024
Sangwook Song
Director · since 2024
Andy Yoo
President, Chief Executive Officer, Director · since 2025
Aejin Hwang
Independent Director · since 2025
Dongho Lee
Independent Director · since 2023
Sangjn Yeo
Independent Director · since 2025
Headquarters & legal address
C/O CORPORATION SERVICE COMPANY
251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
Previous name
AuraSense Therapeutics, LLC
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||